{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Donoghue JF"],"funding":["NINDS NIH HHS","NCI NIH HHS","National Health and Medical Research Council"],"pagination":["E243"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6116191"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(8)"],"pubmed_abstract":["Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ErbB2 Receptor Tyrosine Kinase 4 (ERBB4) is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM. Using RT-qPCR, we quantified mRNA encoding total ERBB4 and known ERBB4 variants in GBM and non-neoplastic normal brain (NNB) samples. Using immunohistochemistry, we characterized the localization of total and phosphorylated ERBB4 (p-ERBB4) and EGFR protein in archived GBM samples and assessed their association with patient survival. Furthermore, we evaluated the effect of ERBB4 phosphorylation on angiogenesis and tumorigenicity in GBM xenograft models. Total <i>ERBB4</i> mRNA was significantly "],"journal":["Cancers"],"pubmed_title":["Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response."],"pmcid":["PMC6116191"],"funding_grant_id":["R01 NS073831","P30 CA008748","APP1117501"],"pubmed_authors":["Mischel PS","Donoghue JF","Wang R","Alexander NW","Longano AB","Tabar V","Kerr LT","Adams TE","Gottardo NG","Johns TG","Greenall SA"],"additional_accession":[]},"is_claimable":false,"name":"Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.","description":"Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ErbB2 Receptor Tyrosine Kinase 4 (ERBB4) is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM. Using RT-qPCR, we quantified mRNA encoding total ERBB4 and known ERBB4 variants in GBM and non-neoplastic normal brain (NNB) samples. Using immunohistochemistry, we characterized the localization of total and phosphorylated ERBB4 (p-ERBB4) and EGFR protein in archived GBM samples and assessed their association with patient survival. Furthermore, we evaluated the effect of ERBB4 phosphorylation on angiogenesis and tumorigenicity in GBM xenograft models. Total <i>ERBB4</i> mRNA was significantly ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2025-04-26T13:59:42.333Z","creation":"2019-03-26T23:54:06Z"},"accession":"S-EPMC6116191","cross_references":{"pubmed":["30044378"],"doi":["10.3390/cancers10080243"]}}